IVF News & Events

INVO Fertility announced that on April 23, it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company that it is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Specifically, the company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The delay in filing is due to additional time required to review certain complex accounting matters, including the tax provision accounting, certain warrant accounting, and variable interest entity accounting. The notice has no immediate effect on the listing of the company's common stock on Nasdaq.

INVO Fertility announced the adoption of time-lapse incubation technology at its Wisconsin clinic. "This integration reflects INVO's commitment to providing high-quality, modern laboratory care and innovative patient solutions, and to investing in laboratory excellence and clinical quality across its growing network of clinics," the company said.

INVO Fertility announced that its Wisconsin Fertility Institute clinic has joined the Progyny network. Progyny provides fertility and family-building benefits to an estimated 7.2 million covered lives through over 600 employers and plan sponsors nationwide. WFI's participation in the Progyny network significantly expands the clinic's access to employer-sponsored patients and meaningfully increases its addressable market within Wisconsin and surrounding regions. Eligible patients now have in-network access to WFI's comprehensive suite of reproductive services, including diagnostic testing, in vitro fertilization, fertility preservation, and other advanced treatment options. Progyny's clinically integrated benefit design simplifies financial and administrative processes for patients, reducing barriers to care and supporting improved treatment utilization and outcomes. Progyny has become a major force in addressing the greatest patient challenges in the fertility industry-access and affordability.